Nurix Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NRIX Nasdaq 2836 www.nurixtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nurix Therapeutics, Inc.

Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed - Feb 4th, 2026 8:20 pm
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Feb 2nd, 2026 8:02 pm
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Feb 2nd, 2026 7:29 am
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Jan 30th, 2026 7:47 am
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Jan 28th, 2026 3:35 pm
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - Jan 28th, 2026 2:01 pm
Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility - Jan 25th, 2026 10:08 am
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Jan 23rd, 2026 8:00 am
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - Jan 12th, 2026 5:00 am
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:00 am
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Dec 22nd, 2025 7:03 am
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Dec 21st, 2025 5:09 pm
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Dec 21st, 2025 7:57 am
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Dec 21st, 2025 5:08 am
Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Dec 9th, 2025 12:23 pm
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? - Dec 8th, 2025 2:07 pm
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - Dec 8th, 2025 6:00 am
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - Dec 6th, 2025 7:30 am
Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast - Dec 2nd, 2025 1:11 pm
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - Dec 1st, 2025 5:00 am